EUVIMEDEUVIMED entdecken
Crossref

Role and mechanism of LINC02390 and its potential target genes, CLECL1 and CD69, in immune microenvironment of lung adenocarcinoma

Haichao Luo, Ran Chen, Changying Wang, Qitian Chen

Technology and Health Care · 2025

DOI: 10.3233/thc-241452 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Technology and Health Care, 2025. Verfasst von Haichao Luo und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Antigens, Differentiation, T-Lymphocyte, Tumor Microenvironment, Adenocarcinoma of Lung, Antigens, CD. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Targeted therapy and immunotherapy has brought new hope to patients with lung adenocarcinoma (LUAD) with their applications. However, the prognosis of LUAD patients is still unpromising. OBJECTIVE: It is particularly important to find the biomarkers that can predict the prognosis of LUAD. In our previous study, we found that patients with high expression of LINC02390 had a better prognosis. The clinical significance of LINC02390 and its potential target genes, CLECL1 and CD69, in the prognosis of LUAD and its role in the immune microenvironment were explored. METHODS: Through the survival analysis, LINC02390 and its potential target genes, CLECL1 and CD69, were identified as good prognostic factors for LUAD. According to GO and KEGG analyses, LINC02390-related genes were identified potentially involved in immune-related signaling pathways. Gene mutations and their relationship with immune cell infiltration were verified through the online cbioportal and TIMER database. RESULTS: CD69 was found to positively associate with CD8 [Formula: see text] T cells and CLECL1 was also positively associated with CD4 [Formula: see text] T cells. A high expression of CD69 in CD8 [Formula: see text] T cells was identified through the single-cell sequencing dataset GSE111894. Finally, CLECL1 and CD69 were lowly expressed in clinical tissue samples with LUAD by immunohistochemical staining. CONCLUSIONS: LINC02390 and its possible target genes, CLECL1 and CD69, may be potential targets for the immunotherapy in LUAD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, Differentiation, T-LymphocyteTumor MicroenvironmentAdenocarcinoma of LungAntigens, CDLung NeoplasmsLectins, C-TypeHumansRNA, Long NoncodingPrognosisBiomarkers, TumorSurvival AnalysisCD69 Antigens

Stichwörter der Autor:innen

CD69CLECL1LINC02390immune microenvironmentimmunotherapylung adenocarcinoma

Substanzen

Antigens, Differentiation, T-LymphocyteAntigens, CDLectins, C-TypeRNA, Long NoncodingBiomarkers, TumorCD69 Antigens

Zitieren

APA

Luo, H., Chen, R., Wang, C., & Chen, Q. (2025). Role and mechanism of LINC02390 and its potential target genes, CLECL1 and CD69, in immune microenvironment of lung adenocarcinoma. Technology and Health Care. https://doi.org/10.3233/thc-241452

Vancouver

Luo H, Chen R, Wang C, Chen Q. Role and mechanism of LINC02390 and its potential target genes, CLECL1 and CD69, in immune microenvironment of lung adenocarcinoma. Technology and Health Care. 2025. doi:10.3233/thc-241452

BibTeX
@article{Luo2025,
  author = {Luo, Haichao and Chen, Ran and Wang, Changying and Chen, Qitian},
  title = {Role and mechanism of LINC02390 and its potential target genes, CLECL1 and CD69, in immune microenvironment of lung adenocarcinoma},
  journal = {Technology and Health Care},
  year = {2025},
  doi = {10.3233/thc-241452}
}
Kostenlos starten →